Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects

Pharmaceutics. 2023 Jul 1;15(7):1860. doi: 10.3390/pharmaceutics15071860.

Abstract

Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.

Keywords: electrophysiological effects; morphological effects; niosomes; optogenetics.

Grants and funding

This research was funded in part by grants RTI2018-098969-B-I00, PRE2019-087693, DTS19/00175, and PDC2022-133952-100 from the Spanish “Ministerio de Ciencia, Innovación y Universidades” and by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 899287 (NeuraViPeR).